A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Acronyms PRIORITIZE HF
- Sponsors AstraZeneca
- 27 Sep 2019 Planned primary completion date changed from 12 Oct 2020 to 14 Apr 2020.
- 27 Sep 2019 Status changed from suspended to recruiting.
- 15 Jul 2019 Planned End Date changed from 28 May 2020 to 12 Oct 2020.